Matthew W. Foehr
2013 - Ligand Pharmaceuticals
In 2013, Matthew W. Foehr earned a total compensation of $2M as Executive VP and Chief Operating Officer at Ligand Pharmaceuticals, a 61% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $184,050 |
---|---|
Option Awards | $1,012,371 |
Salary | $368,101 |
Stock Awards | $398,176 |
Other | $2,767 |
Total | $1,965,465 |
Foehr received $1M in option awards, accounting for 52% of the total pay in 2013.
Foehr also received $184.1K in non-equity incentive plan, $368.1K in salary, $398.2K in stock awards and $2.8K in other compensation.
Rankings
In 2013, Matthew W. Foehr's compensation ranked 3,960th out of 12,286 executives tracked by ExecPay. In other words, Foehr earned more than 67.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 3,960 out of 12,286 | 68th |
Division Manufacturing | 1,339 out of 4,612 | 71st |
Major group Chemicals And Allied Products | 365 out of 1,462 | 75th |
Industry group Drugs | 255 out of 1,156 | 78th |
Industry Pharmaceutical Preparations | 208 out of 890 | 77th |
Source: SEC filing on April 12, 2016.
Foehr's colleagues
We found four more compensation records of executives who worked with Matthew W. Foehr at Ligand Pharmaceuticals in 2013.